Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Signature Bioscience to Build Drug Discovery Infrastructure with $43M Placement

NEW YORK, July 9 - Having raised $43 million in a private placement, Signature Bioscience now hopes to complete its transition from early-stage technology company to provider of drug discovery services, CEO Mark McDade told GenomeWeb Monday.

In addition to hiring new staff and signing on a partner to build instrumentation for the company's Multipole Coupling Spectroscopy (MCS) technology, Signature is also looking to acquire one to two businesses within the next six months to fill out its capabilities in biology and chemistry, McDade said.

The company has already began evaluating potentail acqiusitions, McDade said, and plans to target companies that can help Signature identify potential drug targets and design synthetic compounds to interact with them.

Signature's MCS technology uses radio frequency waves to study protein structure and drug-protein interactions without requiring researchers to label individual proteins. McDade said the technology also allows researchers to probe drug-protein interactions in real-time and in in vivo -like environments.

"We've worked pretty hard to commercially validate our technology," McDade said. "Now we're in serious negotiations with an instrumentation partner to build an internal supply of [MCS] benchtop equipment."

Three months ago, the Hayward, Calif-based company hired David Spellmeyer, a former executive director of DuPont Pharmaceuticals' Research Laboratory, to become the chief scientific officer and vice president of drug discovery at Signature.

New investors in the fourth round of financing included SG Capital Partners, Vulcan Ventures, MDS Capital Group, China Development Industrial Bank, Tallwood Venture Capital, Lehman Brothers, Lotus Bioscience Ventures, and IRR. With the help of current investors Prospect Venture Partners, and others, the company has so far raised a total of $64 million in venture capital funding since it was founded in 1998.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.